27-09-2006

A new target for cancer therapy has been identified by Monash University scientists investigating the cell signalling pathways that turn on a gene involved in cancer development. A team led by Associate Professor Jun-Ping Liu, from the Department of Immunology, has identified two proteins ...

more

12-09-2006

Pharmexa has been granted a patent in the United States and has received communication of intent to grant from the European patent authorities on GV1003, a new peptide vaccine candidate aimed at the telomerase enzyme which is crucial to cancer cells' ability to divide. The telomerase enzyme, ...

more

01-09-2006

Pharmexa has received the necessary approvals in France regarding the Heptovax Phase II trial with GV1001 in liver cancer and will now initiate recruitment of patients. Approvals in Spain and Germany are expected within the next few weeks. The Heptovax trial is a Pase II trial evaluating the ...

more

17-07-2006

Bioanalytical and diagnostic test methods are often based on the recognition of biomolecules by other biomolecules. However, biochemical events such as these are not directly detectable and must first be converted into physical signals, for example an electrical or optical signal. Since ...

more

19-06-2006

Pharmexa has filed an opposition against the US biotech company Geron's European patent (EP841396) to the European Patent Office (EPO) and has requested an invalidation of three claims in the patent related to peptide vaccines against telomerase. In a decision on 13 June 2006, the European ...

more

02-06-2006

Pharmexa has submitted the application to initiate the Heptovax phase II trial. The trial is planned to start in the third quarter of 2006 and will include up to 41 liver cancer patients. The Heptovax trial is a phase II, open-label trial evaluating the safety and efficacy of GV1001 in ...

more

26-05-2006

Geron Corporation announced the publication of data in Clinical Cancer Research demonstrating the broad efficacy of GRN163L, Geron's telomerase inhibitor drug, against multiple types of breast cancer cells as well as the significant reduction of metastatic activity in vivo. The research was ...

more

17-05-2006

Geron Corporation and TA Therapeutics, Ltd., a joint venture between Geron Corporation and the Biotechnology Research Corporation of Hong Kong (BRC), announced the presentation of studies demonstrating that their small molecule telomerase activator, TAT0002, enhances the anti-viral activity ...

more

26-04-2006

The US patent authorities have issued a patent to Pharmexa on the GV1001 vaccine. GV1001 is Pharmexa's peptide vaccine targeting telomerase, which is currently under preparation for Phase III trials in pancreatic cancer. Pharmexa already has issued and validated patents for the GV1001 vaccine ...

more

21-04-2006

Pharminox Limited announced that it has signed a new agreement with Cancer Research Technology Limited (CRT) to secure rights to a preclinical oncology programme focused on telomere signalling targeted agents (TSTAs). The programme has come out of research by Professor Malcolm Stevens OBE, ...

more